Adherence to clinical practice guidelines for using electroconvulsive therapy in elderly depressive patients.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yrondi Antoine, Blanc Olivier, Anguill Loic, Arbus Christophe, Boudieu Ludivine, Patoz Marie-Camille, Arnould Adeline, Charpeaud Thomas, Genty Jean-Baptiste, Abidine Racan, Redon Maximilien, Rey Romain, Aouizerate Bruno, Bennabi Djamila, El-Hage Wissam, Etain Bruno, Holtzmann Jérôme, Leboyer Marion, Molière Fanny, Richieri Raphaelle Marie, Stéphan Florian, Vaiva Guillaume, Sauvaget Anne, Poulet Emmanuel, Haffen Emmanuel, Courtet Philippe, Fossati Philippe, Llorca Pierre-Michel, Samalin Ludovic
Аннотация
METHODS: In this multicenter, retrospective study including patients aged 65 years or over with MDEs in MDD or BD who have been treated with ECT for MDEs, data on the duration of MDEs and the number of lines of treatment received before ECT were collected. The reasons for using ECT, specifically first-line indications (suicidality, urgency, presence of catatonic and psychotic features, previous ECT response, patient preference) were recorded. Statistical comparisons between groups used standard statistical tests.
RESULTS: We identified 335 patients. The mean duration of MDEs before ECT was about 9 months. It was significantly shorter in BD than in MDD- about 7 and 10 months, respectively. The co-occurrence of chronic medical disease increased the duration before ECT in the MDD group. The presence of first-line indications for using ECT from guidelines did not reduce the duration of MDEs before ECT, except where there was a previous response to ECT. The first-line indications reduced the number of lines of treatment before starting ECT.
CONCLUSION: Even if ECT seems to be a key treatment in the elderly population due to its efficacity and safety for MDEs, the delay before this treatment is still too long.